CA2836103C - Modification-dependent activity assays - Google Patents

Modification-dependent activity assays Download PDF

Info

Publication number
CA2836103C
CA2836103C CA2836103A CA2836103A CA2836103C CA 2836103 C CA2836103 C CA 2836103C CA 2836103 A CA2836103 A CA 2836103A CA 2836103 A CA2836103 A CA 2836103A CA 2836103 C CA2836103 C CA 2836103C
Authority
CA
Canada
Prior art keywords
factor
antibody
recombinant
polypeptide
modification
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2836103A
Other languages
English (en)
French (fr)
Other versions
CA2836103A1 (en
Inventor
Alfred Weber
Andrea ENGELMAIER
Hans Peter Schwarz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical Co Ltd filed Critical Takeda Pharmaceutical Co Ltd
Publication of CA2836103A1 publication Critical patent/CA2836103A1/en
Application granted granted Critical
Publication of CA2836103C publication Critical patent/CA2836103C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6842—Proteomic analysis of subsets of protein mixtures with reduced complexity, e.g. membrane proteins, phosphoproteins, organelle proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G01N33/6857—Antibody fragments
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2440/00—Post-translational modifications [PTMs] in chemical analysis of biological material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicinal Preparation (AREA)
  • Enzymes And Modification Thereof (AREA)
CA2836103A 2011-05-18 2012-05-18 Modification-dependent activity assays Active CA2836103C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161487612P 2011-05-18 2011-05-18
US61/487,612 2011-05-18
PCT/US2012/038704 WO2012159084A1 (en) 2011-05-18 2012-05-18 Modification-dependent activity assays

Publications (2)

Publication Number Publication Date
CA2836103A1 CA2836103A1 (en) 2012-11-22
CA2836103C true CA2836103C (en) 2020-07-14

Family

ID=46208807

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2836103A Active CA2836103C (en) 2011-05-18 2012-05-18 Modification-dependent activity assays

Country Status (11)

Country Link
US (1) US8785139B2 (enExample)
EP (3) EP3943939A1 (enExample)
JP (5) JP6175426B2 (enExample)
AU (2) AU2012255066B2 (enExample)
CA (1) CA2836103C (enExample)
DK (2) DK2710375T3 (enExample)
ES (2) ES2720138T3 (enExample)
PL (2) PL3517956T3 (enExample)
PT (2) PT2710375T (enExample)
TR (1) TR201904997T4 (enExample)
WO (1) WO2012159084A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102375055A (zh) * 2010-08-19 2012-03-14 中国人民解放军军事医学科学院微生物流行病研究所 一种多重检测免疫层析芯片
US10745737B2 (en) * 2012-11-09 2020-08-18 Children's Medical Center Corporation Methods and reagents for glycoproteomics
CN103819907B (zh) * 2014-03-10 2016-04-06 山东理工大学 一种用聚丙二醇与聚乙烯醇对聚肽膜亲水性进行改进的方法
WO2015169602A1 (en) * 2014-05-05 2015-11-12 Noviosmart Method for the serological diagnosis of rheumatoid arthritis.
CN104559207B (zh) * 2015-01-05 2017-02-22 山东理工大学 一种聚氨基甲酸酯与聚丙烯酸改进聚肽膜亲水性与柔顺性的方法
CN104559206B (zh) * 2015-01-05 2017-02-22 山东理工大学 一种聚三亚甲基碳酸酯与聚丙烯酰胺改进聚肽膜亲水性与柔顺性的方法
CN104448841B (zh) * 2015-01-06 2016-08-31 山东理工大学 一种聚乳酸乙醇酸与聚丙烯酸改进聚肽膜亲水性与柔顺性的方法
CN104448843B (zh) * 2015-01-06 2016-10-05 山东理工大学 一种聚己内酯与聚丙烯酸改进聚肽膜亲水性与柔顺性的方法
CN104448842B (zh) * 2015-01-06 2016-08-31 山东理工大学 一种聚乳酸与聚丙烯酸改进聚肽膜亲水性与柔顺性的方法
CN104559224B (zh) * 2015-01-12 2017-02-22 山东理工大学 一种聚丙二醇与水性聚氨酯改进聚肽膜亲水性与柔顺性的方法
CN104530722B (zh) * 2015-01-12 2017-05-03 山东理工大学 一种聚乳酸乙醇酸与羧甲基壳聚糖改进聚肽膜亲水性与柔顺性的方法
CN104479367B (zh) * 2015-01-12 2016-08-31 山东理工大学 一种聚乳酸与水性聚氨酯改进聚肽膜亲水性与柔顺性的方法
US9804170B2 (en) 2015-02-09 2017-10-31 Bristol-Myers Squibb Company Antibodies to polyethylene glycol
JP6552286B2 (ja) * 2015-06-05 2019-07-31 公立大学法人奈良県立医科大学 凝固第ｖｉｉｉ因子の複合体形成能に関する情報の取得方法および試薬キット
SG11202107497XA (en) 2019-01-23 2021-08-30 Regeneron Pharma Treatment of ophthalmic conditions with angiopoietin-like 7 (angptl7) inhibitors
US11845989B2 (en) 2019-01-23 2023-12-19 Regeneron Pharmaceuticals, Inc. Treatment of ophthalmic conditions with angiopoietin-like 7 (ANGPTL7) inhibitors
CN110118847B (zh) * 2019-05-17 2021-08-10 重庆派金生物科技有限公司 确定多位点peg修饰蛋白质修饰位点的分析方法
EP4298219A1 (en) 2021-02-26 2024-01-03 Regeneron Pharmaceuticals, Inc. Treatment of inflammation with glucocorticoids and angiopoietin-like 7 (angptl7) inhibitors
WO2023021311A1 (en) * 2021-08-20 2023-02-23 Takeda Pharmaceutical Company Limited Selective measurement of human factor viii
CA3244889A1 (en) 2022-03-08 2023-09-14 Equashield Medical Ltd FLUID TRANSFER STATION IN A ROBOTIC PHARMACEUTICAL PREPARATION SYSTEM

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3244030A1 (de) 1982-11-27 1984-05-30 Behringwerke Ag, 3550 Marburg Chromogene verbindungen, verfahren zu ihrer herstellung und ihre verwendung
US5208148A (en) 1990-12-07 1993-05-04 Molecular Probes, Inc. Lipophilic fluorescent glycosidase substrates
EP0603266B1 (en) 1991-08-23 1999-05-12 Molecular Probes, Inc. Use of haloalkyl derivatives of reporter molecules to analyze metabolic activity in cells
US5576424A (en) 1991-08-23 1996-11-19 Molecular Probes, Inc. Haloalkyl derivatives of reporter molecules used to analyze metabolic activity in cells
US5242805A (en) 1991-08-23 1993-09-07 Molecular Probes, Inc. Long wavelength lipophilic fluorogenic glycosidase substrates
US5830912A (en) 1996-11-15 1998-11-03 Molecular Probes, Inc. Derivatives of 6,8-difluoro-7-hydroxycoumarin
US5773236A (en) 1997-04-25 1998-06-30 Molecule Probes, Inc. Assay for glutathiane transferase using polyhaloaryl-substituted reporter molecules
CN1688248A (zh) * 2002-08-22 2005-10-26 贝克顿·迪金森公司 痴呆相关神经疾病的诊断方法
US8133865B2 (en) 2006-12-27 2012-03-13 Nektar Therapeutics von Willebrand factor- and factor VIII-polymer conjugates having a releasable linkage
US9333247B2 (en) * 2007-07-03 2016-05-10 Children's Hospital & Research Center At Oakland Oligosialic acid derivatives, methods of manufacture, and immunological uses
ES2587742T3 (es) * 2007-12-27 2016-10-26 Baxalta GmbH Métodos para diferenciar en una muestra proteína derivada de plasma de proteína recombinante
ES2515365T3 (es) * 2007-12-27 2014-10-29 Baxter International Inc. Procedimiento y composiciones para detectar específicamente moléculas poliméricas fisiológicamente aceptables
BRPI0911266A2 (pt) * 2008-04-03 2015-09-29 Hoffmann La Roche ensaio de fator de crescimento similar à insulina peguilado
CA2740904C (en) * 2008-10-21 2019-01-15 Baxter International Inc. Methods for determining active ingredients in pro-drug peg protein conjugates with releasable peg reagents (in vitro de-pegylation)
US8642737B2 (en) 2010-07-26 2014-02-04 Baxter International Inc. Nucleophilic catalysts for oxime linkage
EP3081233B1 (en) 2009-07-27 2020-12-23 Baxalta GmbH Glycopolysialylation of proteins other than blood coagulation proteins
AU2010281453C1 (en) 2009-07-27 2019-08-15 Takeda Pharmaceutical Company Limited Blood coagulation protein conjugates
GB2488532B (en) * 2011-02-18 2013-06-05 Sca Ipla Holdings Inc Communication units and methods for control change notification in broadcast communication

Also Published As

Publication number Publication date
JP6863950B2 (ja) 2021-04-21
US20120329072A1 (en) 2012-12-27
PT2710375T (pt) 2019-05-08
PL2710375T3 (pl) 2019-07-31
WO2012159084A1 (en) 2012-11-22
TR201904997T4 (tr) 2019-05-21
DK3517956T3 (da) 2021-10-11
JP2023081972A (ja) 2023-06-13
PL3517956T3 (pl) 2021-12-20
ES2893605T3 (es) 2022-02-09
JP7618714B2 (ja) 2025-01-21
JP7242627B2 (ja) 2023-03-20
US8785139B2 (en) 2014-07-22
ES2720138T3 (es) 2019-07-18
EP3943939A1 (en) 2022-01-26
JP2019035765A (ja) 2019-03-07
DK2710375T3 (en) 2019-04-29
PT3517956T (pt) 2021-10-15
EP2710375A1 (en) 2014-03-26
EP3517956A1 (en) 2019-07-31
AU2012255066A1 (en) 2013-05-02
JP2021063816A (ja) 2021-04-22
JP6175426B2 (ja) 2017-08-02
CA2836103A1 (en) 2012-11-22
AU2012255066B2 (en) 2016-06-02
JP2014524010A (ja) 2014-09-18
JP2017161536A (ja) 2017-09-14
EP3517956B1 (en) 2021-09-08
AU2016203387A1 (en) 2016-06-16
AU2016203387B2 (en) 2018-01-25
EP2710375B1 (en) 2019-03-13

Similar Documents

Publication Publication Date Title
CA2836103C (en) Modification-dependent activity assays
Swanson et al. Evaluation of methods to detect and characterize antibodies against recombinant human erythropoietin
HK40067577A (en) Modification-dependent activity assays
KR20100004107A (ko) 인간 ｆｃ 감마 수용체 ⅲ
HK40010723A (en) Modification-dependent activity assays
HK40010723B (en) Modification-dependent activity assays
EP1469317B1 (en) Reagent for detecting anti-phospholipid antibody
US20090075298A1 (en) Method of analyzing enzyme
US20240353431A1 (en) Selective measurement of human factor viii
EP2936153B1 (en) Sensitive multiplex immunoassay for soluble fibroblast growth factor receptors
CA2476979A1 (en) Assay for anti-ingap antibodies
Engelmaier et al. Selective human factor VIII activity measurement after analytical in‐line purification
US20170212117A1 (en) Method and kit for detecting bacterial infection
WO2025017135A1 (en) Screening methods for antibody compositions
Layshock Analytical Techniques for Biopharmaceutical Development—ELISA

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20170503